Older Melanoma Patients Respond Better to Anti-PD-1 Immunotherapies, Study Shows

Source: Immuno-Oncology News, June 2018

Older melanoma patients respond better to the anti-PD-1 immunotherapy Keytruda(pembrolizumab), according to new data from a multinational study. Researchers are attributing these differences to a reduced immunosuppressive tumor environment in older patients.

The study with these findings, “Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations,” was published in Clinical Cancer Research.

read the original full article